Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: An analysis from Diuretic Optimization Strategies in Acute Heart Failure

被引:31
作者
Shah, Ravi V. [2 ,5 ]
McNulty, Steven [3 ]
O'Connor, Christopher M. [4 ]
Felker, G. Michael [4 ]
Braunwald, Eugene [1 ,5 ]
Givertz, Michael M. [1 ,5 ]
机构
[1] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA
[3] Duke Clin Res Inst, Durham, NC USA
[4] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA
[5] Harvard Univ, Sch Med, Boston, MA USA
关键词
BLOOD UREA NITROGEN; ASSOCIATION; TOLVAPTAN; MORTALITY;
D O I
10.1016/j.ahj.2012.08.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Results from the DOSE-AHF study suggest that an initial continuous infusion of loop diuretics is not superior to bolus dosing with regard to clinical endpoints in acute heart failure. We hypothesized that outpatient furosemide dose was associated with congestion and poorer renal function and explored the hypothesis that a continuous infusion may be more effective in patients on higher outpatient diuretic doses. Methods The DOSE-AHF study randomized 308 patients within 24 hours of admission to high versus low initial intravenous diuretic dose given as either a continuous infusion or bolus. We compared baseline characteristics and assessed associations between mode of administration (bolus vs continuous) and outcomes in patients receiving high-dose (>= 120 mg furosemide equivalent, n = 177) versus low-dose (<120 mg furosemide equivalent, n = 131) outpatient diuretics. Results Patients on higher doses of furosemide were less frequently on renin-angiotensin system inhibitors (P = .01) and had worse renal function and more advanced symptoms. There was a significant interaction between outpatient dose and mode of therapy (P = .01) with respect to net fluid loss at 72 hours after adjusting for creatinine and intensification strategy. Admission diuretic dose was associated with an increased risk of death or rehospitalization at 60 days (adjusted hazard ratio 1.08 per 20-mg increment in dose, 95% CI 1.01-1.16, P = .03). Conclusions In acute heart failure, patients on higher diuretic doses have greater disease severity and may benefit from an initial bolus strategy. (Am Heart J 2012;164:862-8.)
引用
收藏
页码:862 / 868
页数:7
相关论文
共 19 条
  • [1] Abdallah JG, 2001, J AM SOC NEPHROL, V12, P1335, DOI 10.1681/ASN.V1271335
  • [2] Diuretic therapy
    Brater, DC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (06) : 387 - 395
  • [3] Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction
    Cooper, HA
    Dries, DL
    Davis, CE
    Shen, YL
    Domanski, MJ
    [J]. CIRCULATION, 1999, 100 (12) : 1311 - 1315
  • [4] Relation of loop diuretic dose to mortality in advanced heart failure
    Eshaghian, Shervin
    Horwich, Tamara B.
    Fonarow, Gregg C.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (12) : 1759 - 1764
  • [5] Diuretic Strategies in Patients with Acute Decompensated Heart Failure
    Felker, G. Michael
    Lee, Kerry L.
    Bull, David A.
    Redfield, Margaret M.
    Stevenson, Lynne W.
    Goldsmith, Steven R.
    LeWinter, Martin M.
    Deswal, Anita
    Rouleau, Jean L.
    Ofili, Elizabeth O.
    Anstrom, Kevin J.
    Hernandez, Adrian F.
    McNulty, Steven E.
    Velazquez, Eric J.
    Kfoury, Abdallah G.
    Chen, Horng H.
    Givertz, Michael M.
    Semigran, Marc J.
    Bart, Bradley A.
    Mascette, Alice M.
    Braunwald, Eugene
    O'Connor, Christopher M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) : 797 - 805
  • [6] Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure - The EVEREST clinical status trials
    Gheorghiade, Mihai
    Konstam, Marvin A.
    Burnett, John C., Jr.
    Grinfeld, Liliana
    Maggioni, Aldo P.
    Swedberg, Karl
    Udelson, James E.
    Zannad, Faiez
    Cook, Thomas
    Ouyang, John
    Zimmer, Christopher
    Orlandi, Cesare
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12): : 1332 - 1343
  • [7] Acute Heart Failure Syndromes
    Gheorghiade, Mihai
    Pang, Peter S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 53 (07) : 557 - 573
  • [8] 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
    Hunt, Sharon Ann
    Abraham, William T.
    Chin, Marshall H.
    Feldman, Arthur M.
    Francis, Gary S.
    Ganiats, Theodore G.
    Konstam, Marvin A.
    Mancini, Donna M.
    Michl, Keith
    Oates, John A.
    Rahko, Peter S.
    Silver, Marc A.
    Stevenson, Lynne Warner
    Yancy, Clyde W.
    Jessup, Mariell
    Casey, Donald E.
    [J]. CIRCULATION, 2009, 119 (14) : E391 - E479
  • [9] Defining Success in Heart Failure The End-Point Mess
    Jessup, Mariell
    [J]. CIRCULATION, 2010, 121 (18) : 1977 - 1980
  • [10] Effects of oral tolvaptan in patients hospitalized for worsening heart failure - The EVEREST outcome trial
    Konstam, Marvin A.
    Gheorghiade, Mihai
    Burnett, John C., Jr.
    Grinfeld, Liliana
    Maggioni, Aldo P.
    Swedberg, Karl
    Udelson, James E.
    Zannad, Faiez
    Cook, Thomas
    Ouyang, John
    Zimmer, Christopher
    Orlandi, Cesare
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (12): : 1319 - 1331